Management of Non-ST-Elevation Acute Coronary Syndrome

Rationale for Beta-Blocker Therapy

• The European Society of Cardiology recommends beta-blockers as a cornerstone of initial medical management in non-ST-elevation acute coronary syndrome (NSTE-ACS) due to their ability to reduce myocardial oxygen demand by decreasing heart rate and blood pressure 1
• Beta-blockers are particularly effective when myocardial ischemia is suspected with tachycardia or hypertension, and have a proven mortality benefit in patients with reduced left ventricular function post-ACS 2
• The American College of Cardiology suggests that beta-blockers reduce the risk of recurrent MI and heart failure hospitalization in patients with NSTE-ACS 2

Implementation Strategy

• The European Society of Cardiology recommends initiating oral metoprolol immediately in patients with NSTE-ACS, with a target heart rate of 50-60 beats per minute 2
• The American College of Cardiology suggests titrating metoprolol upward over several days to weeks as tolerated, while monitoring for hypotension, bradycardia, or heart failure 2

Additional Guideline-Directed Management

• The European Society of Cardiology recommends dual antiplatelet therapy with aspirin and a P2Y12 inhibitor (ticagrelor or prasugrel preferred over clopidogrel) for 12 months in patients with NSTE-ACS 5, 2
• The American College of Cardiology suggests initiating high-intensity statin therapy immediately, targeting LDL-C <70 mg/dL, in patients with NSTE-ACS 5, 2
• The European Society of Cardiology recommends starting an ACE inhibitor within 24 hours in patients with diabetes and hypertension 2
• The American College of Cardiology suggests using risk stratification tools such as serial troponin measurements, continuous ECG monitoring, and risk score calculation (TIMI or GRACE) to guide management in patients with NSTE-ACS 6